CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,884 enrolled
Drug / intervention
aspirin +2 moredrug
Likely dose
aspirin 81mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01995370
NCT01995370Phase 4Completed
CompareCT.gov

Cilostazol Stroke Prevention Study for Antiplatelet Combination

Japan Cardiovascular Research Foundation·interventional·Posted Nov 26, 2013·Updated Mar 28, 2019

In Brief

A Phase 4 clinical trial evaluating aspirin, clopidogrel, and 1 other intervention for Noncardioembolic Cerebral Infarction. Completed, enrolled 1,884 participants across 1 site.

Detailed Summary

To examine the efficacy and safety of dual antiplatelet therapy (DAPT) including cilostazol (Pletaal OD Tablet ®) in comparison with antiplatelet monotherapy (excluding cilostazol) for secondary prevention of ischemic stroke in high-risk patients for stroke

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNoncardioembolic Cerebral Infarction
CountriesJapan
CollaboratorsOtsuka Pharmaceutical Co., Ltd.

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 26, 2013
Enrollment StartDec 13, 2013
Primary CompletionDec 7, 2018
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 12.6 years ago

Interventions

aspirindrug

Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.

clopidogreldrug

Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.

cilostazoldrug

Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.